[{"data":1,"prerenderedAt":254},["ShallowReactive",2],{"$f3u2oi6wjxnls6":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":22,"top_modalities":52,"top_diseases":82,"top_companies":115,"key_results":140,"trends":213,"previous_editions":222,"comparison":226,"highlighted_classes":250},1,"aasld-2026","AASLD","aasld","The Liver Meeting (AASLD) 2026",2026,"Gastroenterology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},2873,946,199,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 4":4,"Phase 2\u002F3":20,"Phase 3":21},20,3,45,6,38,[23,26,29,32,34,37,40,43,46,49],{"name":24,"count":25,"share":20},"GLP1R",59,{"name":27,"count":28,"share":20},"THRB",55,{"name":30,"count":21,"share":31},"HBV Pol",4,{"name":33,"count":21,"share":31},"NMDAR",{"name":35,"count":36,"share":31},"ABCC2",36,{"name":38,"count":39,"share":31},"CD274",34,{"name":41,"count":42,"share":18},"GABRA2",33,{"name":44,"count":45,"share":18},"NTCP",31,{"name":47,"count":48,"share":18},"PPARD",30,{"name":50,"count":51,"share":18},"PPARA",26,[53,57,61,65,69,73,75,79],{"name":54,"count":55,"share":56},"Small molecules",646,68,{"name":58,"count":59,"share":60},"Peptides",112,12,{"name":62,"count":63,"share":64},"Non-antibody therapeutic proteins",92,10,{"name":66,"count":67,"share":68},"Monoclonal antibodies",83,9,{"name":70,"count":71,"share":72},"Oligonucleotide and RNA therapeutics",52,5,{"name":74,"count":19,"share":72},"Carbohydrate, lipid and polymer therapeutics",{"name":76,"count":77,"share":78},"Blood, tissue and cell-derived products",23,2,{"name":80,"count":81,"share":78},"Natural-product mixtures and botanicals",18,[83,87,90,94,98,100,103,106,110,113],{"name":84,"count":85,"share":86},"Cirrhosis",179,19,{"name":88,"count":89,"share":81},"metabolic dysfunction-associated steatohepatitis (MASH)",174,{"name":91,"count":92,"share":93},"metabolic dysfunction-associated steatotic liver disease (MASLD)",138,15,{"name":95,"count":96,"share":97},"hepatocellular carcinoma (HCC)",122,13,{"name":99,"count":59,"share":60},"hepatic fibrosis",{"name":101,"count":102,"share":64},"hepatitis B (HBV)",90,{"name":104,"count":105,"share":68},"primary biliary cholangitis (PBC)",89,{"name":107,"count":108,"share":109},"alcoholic liver disease (ALD)",74,8,{"name":111,"count":112,"share":31},"Chronic Hepatitis B (CHB)",41,{"name":114,"count":21,"share":31},"Portal Hypertension (PH)",[116,119,121,124,126,128,131,133,135,138],{"name":117,"count":118,"share":109},"Gilead Sciences",73,{"name":120,"count":71,"share":72},"Madrigal Pharmaceuticals",{"name":122,"count":123,"share":31},"Novo Nordisk",39,{"name":125,"count":21,"share":31},"Merck",{"name":127,"count":36,"share":31},"TPG Capital",{"name":129,"count":130,"share":31},"GSK",35,{"name":132,"count":42,"share":18},"Eton Pharmaceuticals",{"name":134,"count":51,"share":18},"Genentech",{"name":136,"count":137,"share":78},"Ipsen",21,{"name":139,"count":86,"share":78},"Bristol Myers Squibb",[141,150,157,164,170,178,185,192,199,206],{"title":142,"drug":143,"company":145,"phase":147,"disease":84,"finding":148,"url":149},"Rice recombinant versus plasma-derived human albumin in liver cirrhosis",{"name":144,"slug":145,"named_as":146},"albumin (human)",null,"OsrHSA","Phase 3","Adverse events (OsrHSA, 87.8%; pHSA, 86.4%) or serious adverse events (OsrHSA, 12.2%; pHSA, 10.5%) were comparable.","https:\u002F\u002Fwww.aasld.org\u002Fsites\u002Fdefault\u002Ffiles\u002F2026-10\u002F2026%20TLM%20Abstracts.pdf#abstract-1501",{"title":151,"drug":152,"company":145,"phase":147,"disease":154,"finding":155,"url":156},"Durable and newly emergent treatment response during a 24-WEEK follow-up in a finite lonafarnib treatment regimen: extended analyses from the phase 3 D-LIVR trial",{"name":153,"slug":153},"lonafarnib","hepatitis D (HDV)","The composite response rate improved up to 40% after 24 weeks off treatment in both the LNF\u002FRTV treatment arm (EOS composite response rate of 14.2% compared to 10.1% at EOT) and in the LNF\u002FRTV + PEG treatment arm (EOS composite response rate of 26.4% compared to 19.2% at EOT).","https:\u002F\u002Fwww.aasld.org\u002Fsites\u002Fdefault\u002Ffiles\u002F2026-10\u002F2026%20TLM%20Abstracts.pdf#abstract-0141",{"title":158,"drug":159,"company":129,"phase":161,"disease":104,"finding":162,"url":163},"Impact of linerixibat, an ileal bile acid transporter (IBAT) inhibitor, on fat- soluble vitamin (FSV) absorption in patients with primary biliary cholangitis (PBC)",{"name":160,"slug":160},"linerixibat","Phase 2\u002F3","AEs of FSV decrease\u002Fdeficiency were experienced in 4 (3%) pts receiving linerixibat and 2 (2%) pts receiving placebo, with no meaningful difference in incidence between groups.","https:\u002F\u002Fwww.aasld.org\u002Fsites\u002Fdefault\u002Ffiles\u002F2026-10\u002F2026%20TLM%20Abstracts.pdf#abstract-1251",{"title":165,"drug":166,"company":117,"phase":161,"disease":154,"finding":168,"url":169},"Clinically significant portal hypertension may improve in some patients with chronic hepatitis delta after 48 weeks of bulevirtide treatment – a pooled analysis of phase II\u002FIII clinical trials",{"name":167,"slug":167},"bulevirtide","At W48, 59.1% (13\u002F22) of BLV pts with Baveno-VII rule-in criteria improved to GZ or ruleout vs 25.0% (1\u002F4) of control pts.","https:\u002F\u002Fwww.aasld.org\u002Fsites\u002Fdefault\u002Ffiles\u002F2026-10\u002F2026%20TLM%20Abstracts.pdf#abstract-3243",{"title":171,"drug":172,"company":145,"phase":174,"disease":175,"finding":176,"url":177},"Adjuvant granulocyte colony-stimulating factor after Kasai portoenterostomy for biliary atresia: a phase 2 randomized controlled trial",{"name":173,"slug":173},"filgrastim","Phase 2","biliary atresia","The proportion of subjects with Cholangitis-free transplant-free survival at 12 months was 35% in the KG group and 10% in the KSt group (10%), with log-rank p = 0.0002 and Cox HR 0.36 (95% CI 0.20–0.64); composite events occurred in 18\u002F34 KG vs 39\u002F46 KSt.","https:\u002F\u002Fwww.aasld.org\u002Fsites\u002Fdefault\u002Ffiles\u002F2026-10\u002F2026%20TLM%20Abstracts.pdf#abstract-0273",{"title":179,"drug":180,"company":182,"phase":174,"disease":88,"finding":183,"url":184},"Positive phase 2B clinical results of novel first-in-class pan-PDE inhibitor ZSP1601: safety, antifibrotic and metabolic improvement in MASH participants with F2\u002FF3 fibrosis",{"name":181,"slug":181},"zsp1601","Raynovent Biotech","ZSP1601 reduced liver fat content, with mean percent changes from baseline of -30% (100 mg) and -5% (50 mg) vs. +7% (placebo).","https:\u002F\u002Fwww.aasld.org\u002Fsites\u002Fdefault\u002Ffiles\u002F2026-10\u002F2026%20TLM%20Abstracts.pdf#abstract-0084",{"title":186,"drug":187,"company":145,"phase":174,"disease":91,"finding":190,"url":191},"Safety and efficacy of J2H-1702, a novel 11b-HSD1 inhibitor, in MASLD: a phase 2A randomized controlled trial",{"name":188,"slug":189},"J2H-1702","j2h-1702","At week 12, J2H-1702, especially 200 mg, produced a significant reduction in hepatic fat by MRI-PDFF (−18.7% vs. +3.1%; LS mean difference, −22.3%; p=0.011), alongside improvements in liver enzymes, body weight, and lowdensity lipoprotein cholesterol.","https:\u002F\u002Fwww.aasld.org\u002Fsites\u002Fdefault\u002Ffiles\u002F2026-10\u002F2026%20TLM%20Abstracts.pdf#abstract-3533",{"title":193,"drug":194,"company":196,"phase":174,"disease":88,"finding":197,"url":198},"Efruxifermin drives multidimensional histologic improvement in compensated cirrhosis: an AI-based analysis from the SYMMETRY randomized controlled trial",{"name":195,"slug":195},"efruxifermin","Akero Therapeutics","Notably, at w96, advanced (complete septal and nodular) fibrosis decreased from baseline by 42% in EFX28 and 48% in EFX50, compared to -16% in Pbo (p = 0.02 and p = 0.003, respectively).","https:\u002F\u002Fwww.aasld.org\u002Fsites\u002Fdefault\u002Ffiles\u002F2026-10\u002F2026%20TLM%20Abstracts.pdf#abstract-0066",{"title":200,"drug":201,"company":203,"phase":174,"disease":88,"finding":204,"url":205},"Gastrointestinal tolerability of pemvidutide without dose titration in patients with metabolic dysfunction-associated steatohepatitis from the phase 2B impact trial",{"name":202,"slug":202},"pemvidutide","Altimmune","Treatment discontinuations due to AEs were rare, occurring in 0.0% and 1.2%, in the 1.2 mg and 1.8 mg groups, compared to 3.5% in the placebo group.","https:\u002F\u002Fwww.aasld.org\u002Fsites\u002Fdefault\u002Ffiles\u002F2026-10\u002F2026%20TLM%20Abstracts.pdf#abstract-3575",{"title":207,"drug":208,"company":210,"phase":174,"disease":154,"finding":211,"url":212},"Efficacy of elebsiran (VIR-2218) + tobevibart (vir- 3434) in participants with chronic hepatitis delta infection: patterns of HDV RNA responses through week 96",{"name":209,"slug":209},"elebsiran","Vir Biotechnology","At week 96, 88% (28\u002F32) of participants receiving elebsiran+tobevibart Q4W achieved undetectable HDV RNA (target not detected [TND], no amplification by PCR) and 53% (17\u002F32) achieved ALT normalization (missing equals failure analysis).","https:\u002F\u002Fwww.aasld.org\u002Fsites\u002Fdefault\u002Ffiles\u002F2026-10\u002F2026%20TLM%20Abstracts.pdf#abstract-0136",{"summary":214,"bullets":216},[215],"Small molecules, the most frequent modality, accounted for 68% of drug-linked abstracts, up from 63% in 2025. NMDAR accounted for 4% of drug-linked abstracts, up from 0% in 2025. GABRA2 (3%) and PPARD (3%) were new to the top targets compared with 2025.",[217,218,219,220,221],"GLP1R was the most frequent target (6% of drug-linked abstracts).","Cirrhosis was the most frequent disease (19%).","Gilead Sciences had the largest company share (8%).","GABRA2 accounted for 3% of drug-linked abstracts, up from 0% in 2025.","THRB accounted for 6% of drug-linked abstracts, up from 3% in 2025.",[223],{"year":224,"abstracts":225},2025,2495,{"previous_year":224,"abstracts":227,"targets":229,"modalities":241,"new_in_top_targets":248,"new_in_top_modalities":249},{"previous":225,"current":13,"change_pct":93,"direction":228},"rose",[230,232,233,235,239],{"name":33,"count":21,"share":31,"previous_count":78,"previous_share":231,"direction":228},0,{"name":41,"count":42,"share":18,"previous_count":4,"previous_share":231,"direction":228},{"name":27,"count":28,"share":20,"previous_count":234,"previous_share":18,"direction":228},24,{"name":236,"count":97,"share":4,"previous_count":237,"previous_share":18,"direction":238},"HBsAg",22,"fell",{"name":240,"count":60,"share":4,"previous_count":86,"previous_share":18,"direction":238},"NS5B",[242,245,246],{"name":54,"count":55,"share":56,"previous_count":243,"previous_share":244,"direction":228},442,63,{"name":74,"count":19,"share":72,"previous_count":77,"previous_share":18,"direction":228},{"name":58,"count":59,"share":60,"previous_count":247,"previous_share":64,"direction":228},70,[41,33,47],[],[251],{"name":252,"count":25,"share":20,"previous_count":36,"previous_share":72,"direction":253},"GLP-1 receptor drugs","flat",1793970603080]